We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

46 hedge funds and large institutions have $82.4M invested in PDS Biotechnology in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

476% more capital invested

Capital invested by funds: $14.3M → $82.4M (+$68.1M)

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

117% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 12

44% more funds holding

Funds holding: 32 → 46 (+14)

7.85% more ownership

Funds ownership: 14.13% → 21.98% (+7.8%)

30% less call options, than puts

Call options by funds: $2.75M | Put options by funds: $3.9M

Holders
46
Holders Change
+14
Holders Change %
+43.75%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
26
Increased
10
Reduced
4
Closed
12
Calls
$2.75M
Puts
$3.9M
Net Calls
-$1.15M
Net Calls Change
-$1.15M

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$11.7M
2
BlackRock
BlackRock
New York
+$2.8M
3
WVP
Worth Venture Partners
New Jersey
+$2.72M
4
EI
EAM Investors
California
+$2.18M
5
EGI
EAM Global Investors
California
+$1.47M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.75M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.66M
3
MWM
Minot Wealth Management
Massachusetts
-$207K
4
Marshall Wace
Marshall Wace
United Kingdom
-$201K
5
BFM
Boothbay Fund Management
New York
-$195K
Name Holding Trade Value Shares
Change 		Change in
Stake
IGGA
26
Iron Gate Global Advisors
Utah
$316K +$197K +25,239 New
6CM
27
683 Capital Management
New York
$314K +$195K +25,000 New
CSS
28
Cubist Systematic Strategies
Connecticut
$313K +$195K +24,953 New
Voloridge Investment Management
29
Voloridge Investment Management
Florida
$163K +$101K +12,972 New
OC
30
Oppenheimer & Co
New York
$158K +$98K +12,550 New
Rockefeller Capital Management
31
Rockefeller Capital Management
New York
$83K +$52.2K +6,685 New
EIP
32
Ellis Investment Partners
Pennsylvania
$78K -$11.7K -1,500 -19%
RE
33
RBC Europe
United Kingdom
$77.2K +$11.7K +1,500 +32%
Simplex Trading
34
Simplex Trading
Illinois
$77K +$48.2K +6,174 New
DWA
35
Dorsey Wright & Associates
California
$51K +$31.8K +4,077 New
TRCT
36
Tower Research Capital (TRC)
New York
$40K -$158K -20,256 -86%
CG
37
Cutler Group
California
$36K +$22.6K +2,900 New
Osaic Holdings
38
Osaic Holdings
Arizona
$32K +$7.81K +1,000 +66%
Citigroup
39
Citigroup
New York
$13K +$7.81K +1,000 New
TC
40
Truvestments Capital
Florida
$8K – – –
AWA
41
Arkadios Wealth Advisors
Georgia
$6K – – –
Wells Fargo
42
Wells Fargo
California
$2K -$8 -1 -0.8%
Bank of America
43
Bank of America
North Carolina
$2K +$773 +99 +93%
Federated Hermes
44
Federated Hermes
Pennsylvania
$1K +$843 +108 New
IC
45
Ikarian Capital
Texas
– -$1.75M -383,373 Closed
MWM
46
Minot Wealth Management
Massachusetts
– -$207K -45,439 Closed
Marshall Wace
47
Marshall Wace
United Kingdom
– -$201K -44,232 Closed
BFM
48
Boothbay Fund Management
New York
– -$195K -42,937 Closed
Millennium Management
49
Millennium Management
New York
– -$96K -21,132 Closed
Goldman Sachs
50
Goldman Sachs
New York
– -$95K -20,867 Closed
1
2
3

PDSB Hedge Fund Activity: Q2 2021 in Review

46 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2021, worth a combined $82.4M — up 476% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PDSB positions and 12 closed out — a net gain of 14 holders — while 10 added to existing stakes and 4 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $11.7M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.75M sold.

  • 46 institutional investors held PDS Biotechnology (PDSB) as of Q2 2021, up from 32 in Q1 2021.
  • Funds reported $82.4M of PDS Biotechnology stock for Q2 2021, up 476% quarter-over-quarter.
  • 26 funds opened new PDS Biotechnology positions in Q2 2021 and 12 closed out, a net change of +14 holders.
  • The largest PDS Biotechnology buyer in Q2 2021 was AIGH Capital Management, an estimated $11.7M added.
  • The largest PDS Biotechnology seller in Q2 2021 was Ikarian Capital, an estimated $1.75M sold.

Based on aggregated 13F filings for Q2 2021.